Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy-Reference-Cited by-同舟云学术

Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy

Published:2018-10 Issue: Volume:52 Page:86-93
ISSN:1044-579X
Container-title:Seminars in Cancer Biology
language:en
Short-container-title:Seminars in Cancer Biology

Author:

van Dam Pieter-Jan,Daelemans Sofie,Ross Elizabeth,Waumans Yannick,Van Laere Steven,Latacz Emily,Van Steen Roanne,De Pooter Christel,Kockx Mark,Dirix Luc,Vermeulen Peter B.

Publisher

Elsevier BV

Subject

Cancer Research

Reference55 articles.

1. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy;Schnitt;Mod. Pathol.,2010

2. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis;Pezzella;Am. J. Pathol.,1997

3. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia;Vermeulen;J. Pathol.,2001

4. Lack of angiogenesis in lymph node metastases of carcinomas is growth pattern-dependent;Vermeulen;Histopathology,2002

5. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia;Stessels;Br. J. Cancer,2004

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance;Drug Resistance Updates;2024-11

2. Patterns and Predictors of Recurrence After Curative Resection of Colorectal Liver Metastasis (CRLM);Journal of Gastrointestinal Cancer;2024-08-22

3. Research advances on precision medicine testing in clinical application in colorectal liver metastasis;Chinese Science Bulletin;2024-08-01

4. Vessel co-option: a unique vascular-immune niche in liver cancer;Frontiers in Oncology;2024-04-26

5. Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials;Nature Reviews Clinical Oncology;2024-04-10